High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer

Clinical Cancer Research

Volumn 11, Issue 6, 2005, Pages 2215-2221

  Joshi, Mary Beth Moore ^a   Shirota, Yoshinori ^b   Danenberg, Kathleen D ^c   Conlon, Debbi H ^a   Salonga, Dennis S ^c   Herndon II, James E ^a   Danenberg, Peter V ^b   Harpole Jr , David H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Response Genetics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; COMPLEMENTARY DNA; FLUOROURACIL; FORMALDEHYDE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE P1; MESSENGER RNA; MOLECULAR MARKER; PARAFFIN; PLATINUM DERIVATIVE; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE 1; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; BETA ACTIN GENE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DETERMINATION; ENDOSCOPY; ESOPHAGUS CANCER; ESOPHAGUS TUMOR; EXCISION CROSS COMPLEMENTING GENE 1; FLUORESCENCE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GLUTATHIONE TRANSFERASE PI 1 GENE; HEALTH CENTER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEASUREMENT; MULTIVARIATE ANALYSIS; NONBIOLOGICAL MODEL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; THYMIDYLATE SYNTHASE 1 GENE; TIME; TUMOR BIOPSY; UNIVERSITY;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DNA-BINDING PROTEINS; ENDONUCLEASES; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; RNA, MESSENGER; SURVIVAL RATE; THYMIDYLATE SYNTHASE;

EID: 17044428615     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1387     Document Type: Article

References (31)

1. Medical Council Oesophageal Cancer Working Party. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359:1727-33.
2. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 1999;281:1623-7.
3. Wolfe WG, Vaughn AL, Seigler HF, et al. Survival of patients with carcinoma of the esophagus treated with combined-modality therapy. J Thorac Cardiovasc Surg 1993;105:749-56.
4. Walsh T, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-7.
5. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997;337:161-7.
6. Ando N, Iizuka T, Kakegawa T, et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg 1997;114:205-9.
7. Law S, Fok M, Chow S, et al. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 1997;114:210-7.
8. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared to surgery alone for localized esophageal cancer. N Engl J Med 1998;339:1979-84.
9. Harpole DH, Moore MB, Herndon JA, et al. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2001;7:562-9.
10. Lord RV, Salonga D, Danenberg KD, et al. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, carcinoma sequence. J Gastrointest Surg 2000;4:135-42.
11. Held CA, Stevens J, Livak KJ, et al. Real time quantitative PCR. Genome Res 1996;6:986-94.
12. Gibson UE, Geid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996;6:995-1011.
13. Miller R, Siegmund D. Maximally selected chi-square statistics. Biometrics 1982;38:1011-6.
14. Halpern J. Maximally selected chi-square statistics for small samples. Biometrics 1982;38:1017-23.
15. Roth JA, Pass HI, Flanagan MM, Graeber GM, Rosenberg JC, Steinberg S. Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg 1998;96:242-8.
16. Nygaard K, Hansen S, Hansen HS, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy-the second Scandinavian trial in esophageal cancer. World J Surg 1992;16:1104-10.
17. Schlag PM; for the Chirurgische Arbeitsgemeinschaft fuer Onkologie der Deutschen Gesellwschaft fuer Chirurgie Study Group. Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. Arch Surg 1992;127:1446-50.
18. Manipang T, Vasinanukorn P, Petpichetchian C, et al. Induction chemotherapy in the treatment of patients with carcinoma of the esophagus. J Surg Oncol 1994;56:191-7.
19. Kok TC, van Lanschot J, Siersema PD, van Overhagen H, Tilanus HW; for the Rotterdam Esophageal Tumor Study Group. Neoadjuvant chemotherapy in operable esophageal squamous cell cancer: final report of a phase III multicenter randomized controlled trial [abstract 984]. Proc Am Soc Clin Oncol 1997;16:277a.
20. Crul M, Schellens JHM, Beijnen JH, Maliepaard M. Cisplatin resistance and DNA repair. Cancer Treat Rev 1997;23:341-66.
21. Damia G, Guidi G, D'Inacalci M. Expression of genes involved in nucleoside excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines. Eur J Cancer 1998;34:1783-8.
22. Pratt WB, Ruddon RW, Ensminger WD, Maybaum J. Antimetabolites. In: The anticancer drugs. 2nd ed. Oxford (UK): Oxford University Press; 1994. p. 69-107.
23. Leichman C, Lenz H, Leichman L, et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997;15:3223-9.
24. Yamachika T, Nakanishi H, Inada K, et al. A new prognostic factor for colorectal carcinoma thymidylate synthase, and its therapeutic significance. Cancer 1998;82:70-7.
25. Nakinishi YKM, Bai F, Takayama K, et al. Expression of p53 and glutathione S-transferase-π relates to clinical drug resistance in non-small cell lung cancer. Oncology 1999;57:318-23.
26. Meiter A, Anderson ME. Glutathione. Annu Rev Biochem 1983;55:12-5.
27. Silvestrini R, Veneroni S, Benini E, et al. Expression of p53, glutathione S-transferase-p, and bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. J Natl Cancer Inst 1997;89:639-45.
28. Daidone MG, Ricardi U, Veneroni S, et al. Biological predictors of response to radiotherapy in cervical carcinomas. Int J Oncol 1997;10:41-6.
29. Joshi M, D'Amico T, Harpole D. Molecular biologic substaging of stage 1 NSCLC through immunohistochemistry performed on formalin-fixed, paraffin-embedded tissue. In: Driscoll B, editor. Methods in molecular medicine. Vol. 75. Lung cancer. Vol. 2. Totowa (NJ): Humana Press; 2002. p. 369-88.
30. D'Amico TA. Aloia TA. Moore MB, et al. Molecular biologic substaging of stage I lung cancer according to gender and histology. Ann Thorac Surg 2000;69:882-6.
31. Brabender J, Lord R, Wickramasinghe K, et al. Glutathione S-transferase-π expression is downregulated in patents with Barrett's esophagus and esophageal adenocarcinoma. J Gastrointest Surg 2002;6:359-67.